Recurrent renal stone disease - advances in pathogenesis and clinical management

被引:147
作者
Bihl, G
Meyers, A
机构
[1] Addenbrookes Hosp, Addenbrookes Renal & Dialysis Ctr, Cambridge, England
[2] Johannesburg Hosp, Stone Clin, Johannesburg, South Africa
关键词
D O I
10.1016/S0140-6736(01)05782-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Kidney stones are common in industrialised nations: up to 15% of white men and 6% of all women will develop one stone, with recurrence in about half these people. Risk factors for formation of stones include urinary promoters (calcium, urate, cystine, and sodium) and urinary inhibitors (magnesium, citrate, and nephrocalcin). Acute renal colic can be precipitated by dehydration and reduced urine output, increased protein intake, heavy physical exercise, and various medicines. Such colic manifests as severe loin pain and can be accompanied by frequent urination, dysuria, oliguria, and haematuria. Documentation of stone characteristics is extremely important: type, size, location, and underlying metabolic abnormalities. Such details can be obtained with a combination of biochemical investigations, microscopic examination of urine under polarised light, and an intravenous pyelogram. Ultrasonography and plain abdominal radiographs are also useful, especially for patients unable to tolerate an intravenous pyelogram. Acute therapy includes complete pain relief, rehydration, and encouragement of diuresis. Long-term management encompasses education of patients with regard to diet and fluid intake, control of calciuria, citrate replacement, and treatment of any underlying urinary-tract infection or metabolic abnormality. Stones smaller than 5 mm normally pass spontaneously, whereas larger stones, as big as 2 cm, are best treated with extracorporeal shock-wave lithotripsy. All physicians should have a clear understanding of the pathogenesis and clinical management (acute treatment and prevention of recurrence) of renal stone disease.
引用
收藏
页码:651 / 656
页数:6
相关论文
共 43 条
[1]   MOLECULAR CHARACTERISTICS OF URONIC-ACID-RICH PROTEIN, A STRONG INHIBITOR OF CALCIUM-OXALATE CRYSTALLIZATION INVITRO [J].
ATMANI, F ;
LACOUR, B ;
STRECKER, G ;
PARVY, P ;
DRUEKE, T ;
DAUDON, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 191 (03) :1158-1165
[2]   Plasma phospholipid arachidonic acid content and calcium metabolism in idiopathic calcium nephrolithiasis [J].
Baggio, B ;
Budakovic, A ;
Nassuato, MA ;
Vezzoli, G ;
Manzato, E ;
Luisetto, G ;
Zaninotto, M .
KIDNEY INTERNATIONAL, 2000, 58 (03) :1278-1284
[3]  
BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P977
[4]   NET CALCIUM EFFLUX FROM LIVE BONE DURING CHRONIC METABOLIC, BUT NOT RESPIRATORY, ACIDOSIS [J].
BUSHINSKY, DA .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (05) :F836-F842
[5]   MEDICAL PROGRESS - THE PATHOGENESIS AND TREATMENT OF KIDNEY-STONES [J].
COE, FL ;
PARKS, JH ;
ASPLIN, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (16) :1141-1152
[6]  
COE FL, 1998, NEPHROLITHIASIS PATH, P1
[7]  
CRELLIN J, 1982, APHORISMS HIPPOCRATE, P110
[8]   Effects of inter-α-inhibitor and several of its derivatives on calcium oxalate crystallization in vitro [J].
Dean, C ;
Kanellos, J ;
Pham, H ;
Gomes, M ;
Oates, A ;
Grover, P ;
Ryall, R .
CLINICAL SCIENCE, 2000, 98 (04) :471-480
[9]   Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects [J].
Glauser, A ;
Hochreiter, W ;
Jaeger, P ;
Hess, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (10) :1580-1587
[10]   EFFECT OF URATE ON CALCIUM-OXALATE CRYSTALLIZATION IN HUMAN URINE - EVIDENCE FOR A PROMOTIVE ROLE OF HYPERURICOSURIA IN UROLITHIASIS [J].
GROVER, PK ;
RYALL, RL ;
MARSHALL, VR .
CLINICAL SCIENCE, 1990, 79 (01) :9-15